# A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

> **NCT04398524** · PHASE2 · UNKNOWN · sponsor: **ISA Pharmaceuticals** · enrollment: 65 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of the Oropharynx

## Interventions

- **DRUG:** ISA101b

## Key facts

- **NCT ID:** NCT04398524
- **Lead sponsor:** ISA Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2024-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04398524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04398524, "A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04398524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*